FrancophonIA/ELRC3.0 huggingface dataset:
English: • The PRAC also concluded that there was the need for all MAHs to closely monitor cardiovascular risk and discuss the findings including venous thromboembolic events and possible mechanism(s) and usage pattern and adverse events in patients older than 65 years in the next PSUR.
Estonian: sealhulgas venoosse trombemboolia juhtumeid ja võimalikku mehhanismi või võimalikke mehhanisme ning kõrvalnähte vanematel kui 65-aastastel patsientidel.
English: The CMDh considered the below PRAC recommendation with regard to testosterone containing medicinal products:
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühm arutas ravimiohutuse järelevalve riskihindamiskomitee soovitust testosterooni sisaldavate ravimite kohta.
English: 1 - PRAC recommendation
Estonian: Ravimiohutuse järelevalve riskihindamiskomitee soovitus
English: Protection starts four weeks after vaccination.
Estonian: Kaitse algab 4 nädalat pärast vaktsineerimist.
English: The field study did not bring additional information.
Estonian: Väliuuring lisateavet ei andnud.
English: The whole flock should be vaccinated at the same time.
Estonian: Kõik sama karja linnud tuleb vaktsineerida korraga.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for MS-H vaccine on 14 June 2011.
Estonian: Euroopa Komisjon andis MS-H-vaktsiini müügiloa, mis kehtib kogu Euroopa Liidus, 14. juunil 2011.
English: The full EPAR for MS-H Vaccine can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst MS-H-vaktsiini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The company presented data from laboratory studies and from one field trial.
Estonian: Ettevõte esitas laboriuuringute ja ühe väliuuringu andmed.
English: This summary was last updated in March 2016
Estonian: Kokkuvõtte viimane uuendus: 03-2016.
English: Protection against damage to air sacs lasts for 40 weeks, but the duration of protection against abnormal shells forming is not known.
Estonian: Õhukotikahjustuste kaitse kestab 40 nädalat, munakoorehäirete kaitse kestus ei ole teada.
English: The vaccine has no known side effects.
Estonian: Vaktsiinil ei ole teadaolevaid kõrvalnähte.
English: It should not be used in birds in lay or within five weeks of the start of the laying period.
Estonian: Vaktsiini ei tohi kasutada munevatel lindudel või 5 nädala jooksul enne munemisperioodi algust.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that MS-H Vaccine's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et MS-H-vaktsiini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
English: Any accidental splashing to the face and eyes should be thoroughly washed with water.
Estonian: Vaktsiini juhuslikul silma või näole sattumisel tuleb see kohe veega hoolikalt maha pesta.
English: The person administering the vaccine should wear protective equipment, consisting of gloves and safety glasses to avoid skin and eye injuries which may occur by manipulating the vaccine bottle which is frozen.
Estonian: Vaktsiini manustav isik peab kandma kaitsevahendeid - kaitsekindaid ja kaitseprille -, et vältida nahaja silmakahjustusi, mis võivad juhtuda külmutatud vaktsineerimispudeli käsitsemisel.
English: MS-H Vaccine, like all vaccines, works by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Estonian: MS-H-vaktsiin n-ö õpetab immuunsüsteemi (organismi looduslikke kaitsemehhanisme) kaitsma organismi haiguse eest.
English: This is a summary of the European public assessment report (EPAR) for MS-H Vaccine.
Estonian: See on MS-H-vaktsiini Euroopa avaliku hindamisaruande kokkuvõte.
English: The withdrawal period for MS-H vaccine for meat and eggs is zero days.
Estonian: MS-H-vaktsiini keeluaeg on liha ja munade puhul 0 päeva.
English: Infection with Mycoplasma synoviae may result in difficulty breathing and is also associated with poor quality of the eggshell.
Estonian: Mycoplasma synoviae nakkuse tulemusel võivad tekkida hingamisraskused ja seda nakkust seostatakse samuti munakoore halva kvaliteediga.
English: For practical information about using MS-H Vaccine, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad MS-H-vaktsiini kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: MS-H Vaccine is given as one eye drop into one eye.
Estonian: MS-H-vaktsiini manustatakse üks tilk ühte silma.
English: What is MS-H Vaccine and what is it used for?
Estonian: Mis on MS-H-vaktsiin ja milleks seda kasutatakse?
English: Mycoplasma synoviae strain MS-H vaccine (live attenuated)
Estonian: Bakteri Mycoplasma synoviae tüve MS-H vaktsiin (nõrgestatud elustüvi)
English: It is not intended to provide practical advice on how to use MS-H Vaccine.
Estonian: Hindamisaruandes ei anta MS-H-vaktsiini kasutamise praktilisi nõuandeid.
English: This bacterium causes infections in birds, generally in the lungs and the ‘air sacs', the specialised bags within the bird's body where air is stored during breathing.
Estonian: See bakter põhjustab lindudel nakkusi peamiselt kopsudes ja õhukottides, kuhu koguneb hingamise ajal õhk.
English: MS-H Vaccine
Estonian: MS-H-vaktsiin
English: The laboratory studies showed that MS-H Vaccine reduces damage to the air sacs and reduces the number of eggs with shell abnormalities.
Estonian: Laboriuuringutel selgus, et MS-H-vaktsiin vähendab õhukotikahjustusi ja ebanormaalse koorega munade arvu.
English: MS-H Vaccine is used in young chickens intended to produce eggs for broilers (for meat) and layers (for egg production) to reduce the damage to air sacs and reduce the number of eggs with abnormal shells.
Estonian: MS-H-vaktsiini kasutatakse noorkanadel, kes hakkavad tootma mune lihakanade ja munakanade kasvatamiseks, et vähendada õhukotikahjustusi ja ebanormaalse koorega munade arvu.
English: Other information about MS-H Vaccine:
Estonian: Muu teave MS-H-vaktsiini kohta
English: The field study looked at how vaccinated chickens fared when moved to flocks with a history of Mycoplasma synoviae infection.
Estonian: Väliuuringus uuriti, kuidas reageerisid vaktsineeritud kanad, kui nad paigutati karjadesse, kus oli esinenud Mycoplasma synoviae nakkus.
English: The laboratory studies included a challenge model of Mycoplasma synoviae infection as well as a study looking at the effect of vaccination on eggshell abnormalities.
Estonian: Laboriuuringute hulka kuulus Mycoplasma synoviae nakkuse vastu vaktsineerimata jätmise katsemudel, samuti uuring, mis vaatles vaktsineerimise mõju kooretekkehäiretele.
English: MS-H Vaccine is a vaccine used in chickens from five weeks of age to protect them against Mycoplasma synoviae.
Estonian: MS-H-vaktsiini kasutatakse vähemalt 5 nädala vanustel kanadel kaitseks bakteri Mycoplasma synoviae vastu.
English: Why is MS-H Vaccine approved?
Estonian: Miks MS-H-vaktsiin heaks kiideti?
English: When MS-H Vaccine is given to chickens the immune system recognises the weakened strain as ‘foreign' and makes defences against it.
Estonian: Kui kanadele manustatakse vaktsiini, peab nende immuunsüsteem nõrgestatud tüve võõraks ja tekitab selle vastu antikehi.
English: What are the risks associated with MS-H Vaccine?
Estonian: Mis riskid MS-H-vaktsiiniga kaasnevad?
English: MS-H Vaccine contains a live, attenuated strain of Mycoplasma synoviae.
Estonian: MS-H-vaktsiin sisaldab bakteri Mycoplasma synoviae nõrgestatud elustüve.
English: ‘Attenuated' means that the strain has first been weakened so that it does not cause disease.
Estonian: Nõrgestatud tüvi ei põhjusta haigestumist.
English: In the future, if the animals are exposed to Mycoplasma synoviae, the immune system will be able to respond more quickly.
Estonian: Kui organism puutub hiljem bakteriga Mycoplasma synoviae kokku uuesti, tekivad antikehad kiiremini.
English: How is MS-H Vaccine used?
Estonian: Kuidas MS-H-vaktsiini kasutatakse?
English: What benefits of MS-H Vaccine have been shown in studies?
Estonian: Milles seisneb uuringute põhjal MS-H-vaktsiini kasulikkus?
English: How does MS-H Vaccine work?
Estonian: Kuidas MS-H-vaktsiin toimib?
English: MS-H Vaccine is available as eye drops and can only be obtained with a prescription.
Estonian: MS-H-vaktsiini turustatakse silmatilkadena.
English: 14 July 2017
Estonian: 14. juuli 2017
English: Outcome of a procedure under Article 34 of Directive 2001/82/EC (EMEA/V/A/114)
Estonian: Direktiivi 2001/82/EÜ artikli 34 kohase esildismenetluse (EMEA/V/A/114) tulemused
English: The European Commission issued a decision on 14 July 2017.
Estonian: Euroopa Komisjoni tegi otsuse 14. juulil 2017.
English: The amended product information is available on the 'All documents' tab.
Estonian: Muudetud teave on kättesaadav vahekaardil „Kõik dokumendid“ („All documents“).
English: Denagard 45% (and associated names such as Tiamutin 45%, Denagard 450 mg/g and Denagard vet 450 mg/g) is marketed in Austria, Belgium, Czech Republic, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, the Netherlands, Poland, Portugal, Romania, Slovak Republic and Spain.
Estonian: Denagard 45% (ja sarnaseid nimetusi, nagu Tiamutin 45%, Denagard 450 mg/g ja Denagard vet 450 mg/g) turustatakse Austrias, Belgias, Hispaanias, Itaalias, Kreekas, Leedus, Lätis, Madalmaades, Poolas, Portugalis, Rumeenias, Saksamaal, Slovakkias, Soomes, Tšehhi Vabariigis ja Ungaris.
English: Denagard 45% is authorised in the EU via national procedures.
Estonian: Denagard 45% on Euroopa Liidus heaks kiidetud riiklike menetluste kaudu.
English: What is Denagard 45%?
Estonian: Mis on Denagard 45%?
English: Why was Denagard 45% reviewed?
Estonian: Miks Denagard 45% taotlus läbi vaadati?
English: On 12 April 2017, the European Medicines Agency (the Agency) completed a review of Denagard 45%.
Estonian: 12. aprillil 2017 lõpetas Euroopa Ravimiamet (EMA) Denagard 45% kohta tehtud taotluse läbivaatamise.
English: Tiamulin is a semi-synthetic antibiotic belonging to the pleuromutilin group of antibiotics and works by inhibiting bacterial protein synthesis.
Estonian: Tiamuliin on pleuromutiliinide rühma kuuluv poolsünteetiline antibiootikum, mis inhibeerib bakterite valgusünteesi.
English: Denagard 45% is a veterinary medicinal product available as granules for use in drinking water and contains 450 mg tiamulin hydrogen fumarate per gram product.
Estonian: Denagard 45% on veterinaarravim, mida turustatakse joogivette lisatavate graanulitena ja mis sisaldab 450 mg tiamuliinvesinikfumaraati ravimi ühe grammi kohta.
English: Denagard 45% is indicated for the treatment of swine dysentery, colitis, ileitis, enzootic pneumonia and pleuropneumonia in pigs; chronic respiratory disease in chickens and infectious sinusitis and airsacculitis in turkeys.
Estonian: Denagard 45% on mõeldud düsenteeria, koliidi, ileiidi ning enzootilise pneumoonia ja pleuropneumoonia raviks sigadel, kroonilise hingamiselundite haiguse raviks kanadel ning infektsioosse sinusiidi ja õhukottide põletiku raviks kalkunitel.
English: Questions and answers on Denagard 45% and its associated names EMA/275123/2017
Estonian: Denagard 45% ja sarnaste nimetuste teave EMA/491888/2017
English: Germany noted that there are divergences across Member States in the way the veterinary medicinal product can be used, as seen in the differences in the product information in the countries where Denagard 45% is marketed.
Estonian: Saksamaa tõi esile, et liikmesriikide seas esineb lahknevusi veterinaarravimi kasutusviisides, mis kajastuvad Denagard 45% turustavates riikides ravimiteabes.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that there is a need to harmonise the product information (summary of product characteristics (SPC), labelling and package leaflet) for Denagard 45% in the European Union (EU).
Estonian: EMA veterinaarravimite komitee järeldas, et Denagard 45% ravimiteave (ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht) tuleb Euroopa Liidus ühtlustada.
English: Questions and answers on Denagard 45% and its associated names
Estonian: Denagard 45% ja sarnaste nimetuste teave
English: Based on the evaluation of the currently-available data, the CVMP concluded that the product information for Denagard 45% and its associated names should be harmonised across the EU.
Estonian: Tuginedes praegu kättesaadavatele andmetele, leidis veterinaarravimite komitee, et Denagard 45% ja sarnaste nimetuste ravimiteave tuleb Euroopa Liidus ühtlustada.
English: On 24 August 2016, Germany referred the matter to the CVMP in order to harmonise the product information for Denagard 45% (and associated names) in the EU.
Estonian: 24. augustil 2016 tegi Saksamaa veterinaarravimite komiteele esildise ravimi Denagard 45% (ja sarnaste nimetuste) ravimiteabe ühtlustamiseks Euroopa Liidus.
English: The adequacy of these provisional measures will be reviewed as part of the ongoing Article 20.
Estonian: Nende ajutiste meetmete adekvaatsust hinnatakse uuesti artikli 20 kohases praeguses menetluses.
English: In addition, the EC requested the Agency to give its opinion, as to whether provisional measures were necessary to protect public health.
Estonian: Euroopa Komisjon palus ka EMA hinnangut, kas rahvatervise kaitsmiseks on vaja ajutisi meetmeid.
English: On 9 June 2017 the EC therefore triggered a procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data, and requested the PRAC to assess the impact of the above concerns on the benefit-risk balance of Zinbryta (daclizumab) and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked.
Estonian: Seetõttu algatas Euroopa Komisjon 9. juunil 2017 ravimiohutuse järelevalve andmete põhjal määruse (EÜ) nr 726/2004 artikli 20 kohase menetluse ja palus ravimiohutuse riskihindamise komiteel hinnata nimetatud probleemide mõju Zinbryta (daklisumaab) riski ja kasulikkuse suhtele ning soovitada, kas asjakohased müügiload tuleb säilitada, muuta, peatada või tühistada.
English: • The PRAC considered the procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data, in particular regarding the need for provisional measures in accordance with Article 20(3) of Regulation (EC) No 726/2004 for Zinbryta (daclizumab).
Estonian: • ravimiohutuse riskihindamise komitee arutas määruse (EÜ) nr 726/2004 artikli 20 kohast ravimiohutuse järelevalve andmetest tulenevat menetlust, eelkõige vajadust võtta määruse (EÜ) nr 726/2004 artikli 20 lõike 3 kohased ajutised meetmed Zinbryta (daklisumaabi) suhtes.
English: Therefore, monitoring of serum transaminases levels should continue to be performed at least monthly and more frequently as clinically indicated, further, bilirubin levels should also be tested.
Estonian: Seega tuleb seerumi transaminaaside sisaldust kontrollida edaspidi vähemalt kord kuus ja kliiniliste näidustuste kohaselt veel sagedamini, samuti tuleb kontrollida bilirubiinisisaldust.
English: In addition, consideration should be given to discontinue treatment if an adequate therapeutic response is not achieved.
Estonian: Ka tuleb kaalutleda ravi peatamist, kui ei ole saavutatud piisavat ravivastust.
English: While liver function monitoring continues to be an important measure to detect liver injury, and likely reduce the incidence of severe cases, it is unclear at this stage whether any alternative monitoring regimen would necessarily prevent further severe cases.
Estonian: Kuigi maksafunktsiooni kontrollimine on endiselt tähtis maksakahjustuste tuvastamise meede ning tõenäoliselt vähendab ägedate juhtumite sagedust, ei ole praegu teada, kas on alternatiivseid jälgimisrežiime, millega saab ennetada uusi raskeid juhtumeid.
English: The current recommendation relates only to provisional measures recommended by the PRAC for daclizumab based on the preliminary data available at this time.
Estonian: Praegune soovitus kehtib ainult ravimiohutuse riskihindamise komitee soovitatud ajutiste meetmete kohta daklisumaabi kasutamisel, mis põhinevad soovituse ajal olemas olnud esialgsetel andmetel.
English: Since the initial marketing authorisation further serious cases of liver injury have been reported, including a fatal case despite an attempted liver transplant.
Estonian: Pärast esmase müügiloa andmist on teatatud uutest raskete maksakahjustuste juhtumitest, sealhulgas vaatamata maksasiirdamise katsele toimunud surmajuhtumist.
English: In view of this and while the magnitude and nature of the risk of liver injury is being further investigated, the PRAC considered that provisional measures are needed to limit the use of daclizumab.
Estonian: Nendel põhjustel ja arvestades, et maksakahjustuste riski suurust ja olemust uuritakse täiendavalt, leidis komitee, et daklisumaabi kasutamise piiramiseks on vaja ajutisi meetmeid.
English: Patients exhibiting signs and symptoms suggestive of liver injury should be promptly referred to a hepatologist.
Estonian: Maksakahjustuste nähtude ja sümptomitega patsiendid tuleb otsekohe suunata hepatoloogi juurde.
English: On 7 June 2017, the European Commission (EC) was informed of a fatal case of fulminant liver failure in a patient treated with daclizumab in an ongoing observational study, despite monthly liver function testing performed in accordance with recommendations in the product information.
Estonian: Euroopa Komisjon sai 7. juunil 2017 teate, et vaatlusuuringu ajal on daklisumaabiga ravitud patsient surnud fulminantse maksapuudulikkuse tõttu, kuigi maksafunktsiooni oli kontrollitud kord kuus, nagu soovitati ravimiteabes.
English: Zinbryta (daclizumab) is a centrally authorised medicinal product indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
Estonian: Zinbryta (daklisumaab) on tsentraalse müügiloaga ravim, mis on näidustatud sclerosis multiplex'i relapseeruvate vormide raviks täiskasvanud patsientidel.
English: This was also noted in serious cases that occurred since the marketing authorisation, including the fatal case, therefore while the role of concomitant hepatotoxic medication is not fully elucidated, concomitant use with daclizumab should be cautious.
Estonian: Sama märgiti ka pärast müügiloa andmist esinenud raskete juhtumite, sealhulgas surmajuhtumi korral, seega kuigi koostoimet maksatoksiliste ravimitega ei ole piisavalt põhjalikult uuritud, tuleb nende kasutamisel koos daklisumaabiga olla ettevaatlik.
English: Further, the PRAC took into consideration that interrupting treatment in patients whose disease is well-controlled with daclizumab may induce relapses.
Estonian: Lisaks arvestas ravimiohutuse riskihindamise komitee, et patsientidel, kelle haigust ohjab daklisumaab hästi, võib ravi katkestamine tekitada relapse.
English: HCPs and patients should be informed of the post-marketing fatal case of fulminant liver failure, the common risk of hepatitis and the updated frequency of serious cases of hepatic injury in the light of the new cases.
Estonian: Tervishoiutöötajatele ja patsientidele tuleb teatada müügiloa andmise järgne fulminantse maksapuudulikkuse surmajuhtum, sage hepatiidirisk ja raskete maksakahjustuste uus sagedus, mis on selgunud uute juhtumite järgi.
English: Cases of serious liver injury occurred at any time point between early after treatment initiation to several month after discontinuation and no window of susceptibility to could be defined from cases observed in clinical trials.
Estonian: Rasked maksakahjustused tekkisid mis tahes ajal alates ravi varajasest algusjärgust kuni mitme kuuni pärast ravi lõpetamist ning kliinilistes uuringutes täheldatud juhtumite järgi ei olnud võimalik määratleda suurema sagedusega perioodi.
English: Finally, physicians should consider discontinuing daclizumab treatment if an adequate therapeutic response has not been achieved.
Estonian: Ka peavad arstid kaalutlema daklisumaabiga toimuva ravi peatamist, kui ei ole saavutatud piisavat ravivastust.
English: • The PRAC noted that a fatal case of fulminant liver failure occurred despite adherence to the terms of the marketing authorisation and the risk minimisation measures recommended, including the liver function monitoring.
Estonian: • Ravimiohutuse riskihindamise komitee märkis, et fulminantse maksapuudulikkuse surmajuhtum toimus vaatamata müügiloa tingimuste ja riskivähendusmeetmete järgimisele, sealhulgas maksafunktsiooni kontrollimisele.
English: Analyses performed in the clinical development program to assess potential interactions of daclizumab with potentially hepatotoxic medications showed no clear evidence of increased risk of liver injury with concomitant hepatotoxic medications.
Estonian: Kliinilisel väljatöötamisel tehtud analüüsid, millega hinnati daklisumaabi võimalikke koostoimeid potentsiaalselt maksatoksiliste ravimitega, ei tõendanud selgelt, et maksakahjustuste risk oleks maksatoksiliste ravimite samaaegsel kasutamisel suurem.
English: However, a number of serious hepatic events in patients in daclizumab groups occurred in the setting of concomitant drugs with known hepatotoxic potential, including one fatal autoimmune hepatitis and one non-fatal hepatic failure assessed by an adjudication committee as probable Hy's Law (indicative of a risk of drug-induced severe liver injury).
Estonian: Samas tekkis daklisumaabi uuringurühma patsientidel teadaolevalt maksatoksilise potentsiaaliga ravimite samaaegsel kasutamisel mitmeid raskeid maksaprobleeme, sealhulgas üks fataalne autoimmuunne hepatiit ja üks mittefataalne maksapuudulikkus, mis oli hindamiskomisjoni hinnangul tõenäoline Hy seaduse juhtum (osutab ravimi põhjustatavale raske maksakahjustuse riskile).
English: Therefore, while the magnitude and nature of the risk are being reviewed in depth, having considered the seriousness of the risk and that further RMMs that would be effective in preventing with certainty any new severe cases cannot be identified at this stage, the PRAC considered that it is necessary to provisionally limit the use of daclizumab through restriction of the indication and through preventing its use in patients potentially predisposed to liver injury and provide further recommendations to healthcare professionals (HCPs) and patients in the management of this risk.
Estonian: Sel põhjusel ning kuigi riskide suurust ja olemust uuritakse põhjalikult, arvestades riski suurust ja seda, et praegu ei ole teada muid riskivähendusmeetmeid, mis efektiivselt ennetaksid uusi raskeid juhtumeid, leidis ravimiohutuse riskihindamise komitee, et on vaja ajutiselt piirata daklisumaabi kasutamist, piirates näidustusi ja vältida selle kasutamist patsientidel, kellel võib olla maksakahjustuste tekke eelsoodumus, ning anda tervishoiutöötajatele ja patsientidele selle riski vähendamiseks lisasoovitusi.
English: Caution should also be used when medicinal products of known hepatotoxic potential are used concomitantly.
Estonian: Ettevaatlik tuleb olla ka teadaolevalt maksatoksilise potentsiaaliga ravimite samaaegsel kasutamisel.
English: The RMMs implemented, in particular the monthly liver testing, have not been effective to prevent the fatal case of fulminant hepatic failure.
Estonian: Kasutatud riskivähendusmeetmed, eelkõige igakuine maksafunktsiooni kontrollimine, ei ole olnud fulminantse maksapuudulikkuse surmajuhtumi ennetamisel efektiivsed.
English: The threshold of transaminases elevation for patients not included in clinical trials, and therefore in which treatment initiation is not recommended, should be corrected from above two times the upper normal limit to above or equal to two times that limit.
Estonian: Transaminaaside sisalduse suurenemise lävi patsientidel, kes ei osalenud kliinilistes uuringutes ja kellel seepärast ei soovitata ravi alustada, tuleb korrigeerida seniselt väärtuselt „>2 korda üle referentsvahemiku ülapiiri“ uuele väärtusele „≥2 korda üle referentsvahemiku ülapiiri“.